Denali Therapeutics (NASDAQ:DNLI) Earns Outperform Rating from William Blair

William Blair reissued their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI) in a report released on Wednesday morning,RTT News reports.

Several other research firms have also recently commented on DNLI. JPMorgan Chase & Co. cut their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. Robert W. Baird started coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 price objective on the stock. Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 7th. HC Wainwright cut their price objective on shares of Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, Jefferies Financial Group lifted their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.91.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $21.50 on Wednesday. The company’s fifty day moving average is $23.48 and its 200-day moving average is $24.77. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the company earned ($0.72) EPS. Analysts expect that Denali Therapeutics will post -2.73 EPS for the current year.

Insider Transactions at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 15,558 shares of Denali Therapeutics stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $29.91, for a total transaction of $465,339.78. Following the completion of the sale, the insider now owns 178,066 shares of the company’s stock, valued at approximately $5,325,954.06. The trade was a 8.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Vicki L. Sato sold 1,020 shares of Denali Therapeutics stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $30.00, for a total transaction of $30,600.00. Following the sale, the director now directly owns 111,056 shares of the company’s stock, valued at $3,331,680. The trade was a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 104,518 shares of company stock worth $2,576,982 in the last ninety days. Insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

A number of institutional investors have recently bought and sold shares of DNLI. FMR LLC boosted its holdings in Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after purchasing an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Denali Therapeutics by 63.2% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after purchasing an additional 1,451,770 shares during the period. Point72 Asset Management L.P. bought a new stake in Denali Therapeutics in the 2nd quarter valued at about $24,454,000. Wellington Management Group LLP boosted its holdings in Denali Therapeutics by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after purchasing an additional 903,683 shares during the period. Finally, Integral Health Asset Management LLC bought a new stake in Denali Therapeutics in the 2nd quarter valued at about $7,546,000. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.